American Society of Clinical Oncology (ASCO), 2023
Digital Technology and Patient Care in Oncology: The Deployment of a RPM Solution in 26 Centers in Europe.
Dec 4, 2025
2 minutes
Authors
Arlindo R. Ferreira [1,2], Antoine Lemaire 3, Joseph Rodriguez 3, Jessica Grosjean 4, Joana M Ribeiro 5, Laura Polastro 6, Thomas Grellety 7, Xavier Artignan 8, Katell Le Du 9, Martina Pagliuca 5, Elodie Nouhaud 1, Maximilien Autheman 1, Fabrice Andre 5, Ethan Basch 10, Otto Metzger 11, Mario Di Palma 5, Florian Scotté 5, Ines Maria Vaz Duarte Luis 5, Maria Alice B Franzoi 5.
Affiliation
1. Resilience, Paris ; 2. Catolica Medical School, Universidade Católica Portuguesa, Lisbonne, Portugal ; 3. Centre Hospitalier de Valenciennes ; 4. Centre de cancérologie Les Dentelières, Valenciennes ; 5. Gustave Roussy, Villejuif ; 6. Institut Jules Bordet, Bruxelles, Belgique ; 7. Centre Hospitalier de la Côte Basque, Bayonne ; 8. Institut de Cancérologie et Radiothérapie Bretillien, Rennes, Saint Malo ; 9. Hôpital Privé du Confluent, Nantes ; 10. University of North Carolina, États-Unis.
Introduction
Medical Remote Monitoring based on ePROs (electronic Patient-Reported Outcomes) has demonstrated clinical and organizational benefits through Phase III randomized controlled trials[1-4]. These benefits include:
- Symptom control,
- Quality of life,
- Increased relative dose intensity,
- Reduction in the number of hospitalizations,
- Prolongation of overall survival.
Consequently, in 2022, ESMO published its recommendations regarding medical remote monitoring for routine clinical practice during anti-cancer treatments[5].
Resilience has developed an oncology medical remote monitoring solution (Class IIa medical device) that enables patients to answer a weekly questionnaire (PRO-CTCAE) regarding their common symptoms. Severe symptoms trigger an alert for the healthcare team. Personalized advice and educational resources are also provided to patients via the mobile application.
This study presents the deployment of the Resilience solution in France and Belgium.
Poster presented at the 2023 ASCO (American Society of Clinical Oncology) Congress.
Sources
1. Mir O, Ferrua M, Fourcade A, et al. Digital remote monitoring plus usual care versus usual care in patients treated with oral anticancer agents: the randomized phase 3 CAPRI trial. Nat Med.2022;28(6):1224-1231.
2. Basch E, Schrag D, Henson S, et al. Effect of Electronic Symptom Monitoring on Patient-Reported Outcomes Among Patients With Metastatic Cancer: A Randomized Clinical Trial. JAMA. 2022;327(24):2413-2422.
3. Basch E, Deal AM, Kris MG, et al. Symptom Monitoring With Patient-Reported Outcomes During Routine Cancer Treatment: A Randomized Controlled Trial. J Clin Oncol. 2019 Feb20;37(6):528.
4. Basch E, Deal AM, Dueck AC, et al. Overall Survival Results of a Trial Assessing Patient-Reported Outcomes for Symptom Monitoring During Routine Cancer Treatment. JAMA.2017;318(2):197-198.
5. Di Maio M, Basch E, Denis F, et al. The role of patient-reported outcome measures in the continuum of cancer clinical care: ESMO Clinical Practice Guideline. Ann Oncol. 2022;33(9):878-892. doi:10.1016/j.annonc.2022.04.007.
